Business
Revolutionizing Single-Cell RNA-seq With Automated Cell Counters: Insights From Logos Biosystems
Despite its relative newness, single-cell RNA sequencing (scRNA-seq) has become an essential component of modern biological research.
It can be used to characterize abnormal cell populations, discover and analyze rare cell cellular map networks, and discover subtle yet notable heterogeneities.
scRNA-seq has come a long way since its origins in next-generation sequencers from the late 1990s. While traditional sequencing methods measure a bulk of a cell population to determine its “average genome,” scRNA-seq is significantly more precise. It locates and extracts genomes from individual cells, using each cell to tell part of the genetic story of a greater whole.
Although single-cell sequencing provides valuable information, the process has several drawbacks depending on the method used.
For example, Laser Capture Microdissection (LCM) uses a laser to isolate target cells from a complete solid tissue sample located on a microscope slide. This approach is quick, reliable, and also usable on intact tissues, but it requires the user to identify target cells through visual inspection of their morphology. Cells can also be damaged in the process.
Other methods, like Magnetic-Activated Cell Sorting (MACS) or Fluorescence-Activated Cell Sorting (FACS), come with positives and negatives. Regardless of the approach, advancements in single-cell sequencing technology require significant time and investment, making access to newer and more efficient technologies a barrier to progress.
Overcoming Obstacles With Technological Advancement
When manually counting cells in scRNA-seq analysis, adequately going through each cell can take a huge amount of time and resources. This process also has a high margin of error, sometimes making it difficult to justify the effort.
Moreover, when cell counts are inaccurate for scRNA-seq analysis, overall data quality becomes less reliable, making the research outcomes less reliable and further exacerbating the original issues of time and cost.
With so much time and capital going toward this research, the data it produces should be worthwhile. However, the quality of the data ultimately relies on the quality of the sample before processing, which is where Logos Biosystems and their LUNA-FX7 Automated Cell Counter come in.
Enhancing Research Capabilities
Logos Biosystems is a leader in automated cell counting technology and scRNA-seq analysis and is known for developing the award-winning LUNA Cell Counter family.
Founded in 2008, the company has lived up to its motto of “seeing beyond the cell” by working to improve human health through imaging solutions that help researchers gather quality data in a timely fashion.
Their LUNA series of cell counters specializes in improving research accuracy and efficiency by allowing scientists to spend less time dealing with the monotony of cell counting and more time making valuable observations and implementing solutions.
The LUNA-FX7 Automated Cell Counter gives precise and reliable cell counts. It improves the quality of scRNA-seq analysis and takes less time than other automated counters.
This device has many invaluable features, such as increased size for sample throughput, an expanded cell concentration range, built-in QC software, validation slides for fluorescence, and brightfield to allow for daily QC monitoring and reporting.
Incorporating an automated cell counter like the LUNA-FX7 more broadly in scRNA-seq would improve research outcomes and accelerate scientific discoveries. Having machines take care of menial tasks frees up time for scientists and researchers to use their critical and creative thinking skills to push progress in their respective fields forward in ways machines couldn’t do alone.
Applications for automated cell counting technology are almost limitless, including research into developmental studies, immunology, oncology, neurobiology, diabetes, microbiology, and much more. Being able to quickly and precisely profile, identify, classify, and discover rare or new cell types from across the human body allows greater insight into these disciplines and what they can do for human health and growth.
The exciting future of single-cell RNA sequencing lies in the seamless integration of these automated technologies. As they become more widely adopted, they will pave the way for more innovative discoveries that could shape the understanding of biology and medicine. With technologies like Logos Biosystems’ LUNA-FX7, the question of whether the scientific community can see transformative discoveries is now mute as it continues to work to enhance precision and efficiency in cell evaluation, which is vital for scRNA-seq experiments to be successful to not only advance science but also improve human health and well-being on a global scale.
Business
How Sumatha Kondabolu’s Strategic Insight Shapes the Future of Pharmaceutical and Medical Devices Quality
Byline: Katreen David
Navigating the fast-paced terrain of life sciences demands more than just compliance—it requires a futuristic outlook on pharmaceutical quality assurance. Sumatha Kondabolu exemplifies this forward-thinking mindset with her extensive experience spanning over 20 years. Currently a senior quality specialist and as a quality advisor at Qualio, and a vice-co chair RAPS Quebec LNG, her role involves adapting to regulatory changes while actively redefining how they are interpreted and applied across medical devices and pharmaceuticals and in the life science industry.
Sumatha Kondabolu’s unique perspective merges traditional standards and future challenges. Through her foresight on industry shifts and inventive quality systems, she meets today’s demands head-on and prepares for tomorrow’s challenges.
“Success in life sciences hinges on anticipating future changes and actively reforming industry standards,” Sumatha Kondabolu asserts. “My methods integrate advanced quality systems with the comprehensive depth of regulatory evolution.” This speaks volumes about how she aids organizations in staying ahead in a shifting industry that touches human lives.
Lifelines of Modern Medicine: The Role of Medical Devices and Pharmaceuticals
The medical device and pharmaceutical industries are the bedrock of modern healthcare, delivering innovations that transform patient care and treatment outcomes.
Medical devices range from simple tools like bandages to complex technologies like MRI machines, playing a critical role in diagnosing, monitoring, and treating conditions.
On the other hand, pharmaceuticals encompass everything from vaccines to pain relievers. They provide essential interventions to manage and cure diseases.
Together, these industries fuel advancements in medical science, improve quality of life, and enable healthcare systems to address everyday health needs and global health crises. Their continual evolution makes certain that treatments remain effective and accessible.
Tailoring Quality Systems to Industry Needs
Sumatha Kondabolu’s role in the industry involves developing and implementing quality management systems hands-on. Her extensive experience with various regulatory frameworks, including the Food and Drug Administration (FDA) and International Organization for Standardization (ISO) standards, enables her to tailor solutions that fit the specific needs of each organization.
Kondabolu emphasizes the importance of creating quality systems that are both adaptable and scalable. “Effective quality management is about understanding the present and anticipating the future,” she notes. Her initiatives guarantee that companies are both compliant and well-equipped for upcoming regulatory changes.
Navigating the Evolving Regulatory Sphere
Frequent regulatory updates and technological advancements characterize the life sciences sector. Sumatha Kondabolu’s expertise is crucial in helping organizations navigate these changes smoothly. Her methodology involves continuously monitoring and updating quality systems to align with new regulations and technological innovations.
Staying ahead of regulatory trends means that Sumatha Kondabolu offers a helping hand to companies to mitigate risks and maintain high standards of quality. Ultimately, this supports their growth and success in a competitive industry.
Apart from fulfilling her duties while on the clock, she has also taken on the role of a vice co-chair person for the Regulatory Affairs Professionals Society (RAPS) Quebec LNG. Within the scope of the RAPS, she mentors professionals and students on regulatory affairs.
Her contributions to the vast field of life sciences reflect her deep-rooted understanding of the aspects of art and technology that surround her craft. Sumatha Kondabolu’s adept navigation of regulatory changes and technological advancements turns potential hurdles into stepping stones for innovation. Her forward-thinking blueprints inspire future medical device experts to explore and excel in a field designed to improve and save lives.
-
Tech3 years ago
Effuel Reviews (2021) – Effuel ECO OBD2 Saves Fuel, and Reduce Gas Cost? Effuel Customer Reviews
-
Tech5 years ago
Bosch Power Tools India Launches ‘Cordless Matlab Bosch’ Campaign to Demonstrate the Power of Cordless
-
Lifestyle5 years ago
Catholic Cases App brings Church’s Moral Teachings to Androids and iPhones
-
Lifestyle4 years ago
East Side Hype x Billionaire Boys Club. Hottest New Streetwear Releases in Utah.
-
Tech6 years ago
Cloud Buyers & Investors to Profit in the Future
-
Lifestyle4 years ago
The Midas of Cosmetic Dermatology: Dr. Simon Ourian
-
Health5 years ago
CBDistillery Review: Is it a scam?
-
Entertainment5 years ago
Avengers Endgame now Available on 123Movies for Download & Streaming for Free